IDYA – ideaya biosciences, inc. (US:NASDAQ)
Stock Stats
News
11/18
08:50 am
idya
Low
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
11/18
06:10 am
idya
Low
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
11/18
06:00 am
idya
Low
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
11/12
06:00 am
idya
Medium
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
11/11
06:00 am
idya
Low
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
11/4/2024
06:00 am
idya
4.0%
BEAT
8/6/2024
06:00 am
idya
-3.9%
MISS
11/18
10:24 am
Initiates
Overweight
Stephens & Co.
Low
-2.1%
11/18
08:50 am
Initiates
Overweight
Stephens
Low
-2.4%
11/18
08:50 am
Initiates
Overweight
Stephens
Low
-2.4%
11/5
07:27 am
Downgrades
Outperform
Market Perform
Leerink Partners
Low
-0.3%
11/5
07:19 am
Downgrades
Outperform
Market Perform
Leerink Partners
Low
-0.3%
11/14
04:23 pm
idya
Medium
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
03:14 pm
idya
Low
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: JANUS HENDERSON GROUP PLC
11/14
01:24 pm
idya
Low
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/12
10:33 am
idya
Low
Form SC 13G/A IDEAYA Biosciences, Inc. Filed by: FMR LLC
11/4
04:06 pm
idya
Low
Form 10-Q IDEAYA Biosciences, Inc. For: Sep 30
Show more
Top News Gainers
11/13 Q3/2019 9/30/2019 EPS -0.540 ZacksConsensus -0.670 ActVsEst 0.130 - Beat 47.4%
12/18 Form 8-K IDEAYA Biosciences, Inc. For: Dec 17 14.3%
3/24 Q4/2019 12/31/2019 EPS -0.530 ZacksConsensus -0.570 ActVsEst 0.040 - Beat 12.0%
12/19 Form 3 IDEAYA Biosciences, Inc. For: Dec 17 Filed by: YARNO WENDY L 11.8%
4/7 Form 8-K IDEAYA Biosciences, Inc. For: Apr 06 10.9%
9/9 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. 9.9%
11/19 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 8.9%
4/6 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 8.5%
10/31 IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma 7.9%
1/10 IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ 7.5%
Top News Decliners
11/20 Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress -23.8%
3/11 IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities -20.3%
5/22 Form CERT IDEAYA Biosciences, Inc. -20.1%
8/1 Form 4 IDEAYA Biosciences, Inc. For: Jul 30 Filed by: Hata Yujiro S -11.6%
10/17 IDEAYA Biosciences (NASDAQ: IDYA) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $17.00 price target on the stock. -10.7%
1/16 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
4/1 IDEAYA Biosciences (NASDAQ: IDYA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.0%
1/29 IDEAYA Biosciences (NASDAQ: IDYA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.75 price target on the stock. -6.1%
2/6 Form SC 13G IDEAYA Biosciences, Inc. Filed by: CANAAN X L.P. -4.9%
11/13 Form 8-K IDEAYA Biosciences, Inc. For: Nov 13 -4.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3